Európai Unió - angol - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - split influenza virus, inactivated, containing antigen: a/vietnam/1194/2004 (h5n1) like strain used (nibrg-14) - influenza, human; immunization; disease outbreaks - vaccines - active immunisation against h5n1 subtype of influenza a virus.this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of vaccine prepared from a/vietnam/1194/2004 nibrg-14 (h5n1) (see section 5.1).prepandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted) glaxosmithkline biologicals 3.75 µg should be used in accordance with official guidance.

Írország - angol - HPRA (Health Products Regulatory Authority)

laboratorios hipra s.a. - inactivated infectious bovine rhinotracheitis virus strain la; inactivated parainfluenza-3 virus, strain sf4; inactivated bovine diarrhoea virus strain nadl; live bovine respiratory strain lym-56 - powder and solvent for suspension for injection - - percent - live and inactivated viral vaccines - cattle - immunological - mixed vaccine (l & a)

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 30 microgram/ml - injection, suspension - excipient ingredients: monobasic potassium phosphate; water for injections; thiomersal; calcium chloride dihydrate; dibasic sodium phosphate; potassium chloride; sodium chloride; monobasic sodium phosphate - for active immunization against influenza disease caused by influenza subtype viruses and type b viruses contained in the vaccine.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin -

Európai Unió - angol - EMA (European Medicines Agency)

sanofi pasteur s.a. - influenza virus (inactivated, split) of the following strains:a/california/7/2009 (h1n1)pdm09 - like strain (a/california/7/2009, nymc x-179a)a/hong kong/4801/2014 (h3n2) - like strain (a/hong kong/4801/2014, nymc x-263b)b/brisbane/60/2008 - like strain (b/brisbane/60/2008, wild type) - influenza, human; immunization - vaccines - prophylaxis of influenza in individuals 60 years of age and over, especially in those who run an increased risk of associated complications.the use of idflu should be based on official recommendations.

Európai Unió - angol - EMA (European Medicines Agency)

intervet international bv - inactivated whole avian influenza virus antigen of h5n2 subtype (strain a/duck/potsdam/1402/86) - immunologicals for aves - chicken - for active immunisation of chickens against avian influenza type a, subtype h5.efficacy has been evaluated on the basis of preliminary results in chickens. reduction of clinical signs, mortality and excretion of virus after challenge were shown by three weeks after vaccination.serum antibodies could be expected to persist for at least 12 months after administration of two doses of vaccine.

Európai Unió - angol - EMA (European Medicines Agency)

intervet international bv - inactivated whole avian influenza virus antigen of h5 subtype (strain h5n6, a/duck/potsdam/2243/84) - immunologicals for aves - chicken - for active immunisation of chickens against avian influenza type a, subtype h5.reduction of clinical signs, mortality and excretion of virus after challenge with a virulent h5n1 strain, were shown by two weeks after a single dose vaccination.serum antibodies have been shown to persist in chickens for at least 7 months and studies performed with other vaccine strains show that serum antibodies would be expected to persist in chickens for at least 12 months after administration of two doses of vaccine.

Európai Unió - angol - EMA (European Medicines Agency)

intervet international bv - inactivated whole avian influenza virus antigen of h7n1 subtype (strain, a/ck/italy/473/99) - immunologicals for aves - chicken; ducks - for active immunisation of chickens and ducks against avian influenza type a, subtype h7n1.efficacy has been evaluated on the basis of preliminary results in chickens and ringed teals.in chickens, reduction of clinical signs, mortality, excretion and transmission of virus after challenge were shown by two weeks after a single dose vaccination.in ducks, reduction of excretion and transmission of virus after challenge were shown by two weeks after a single dose vaccination.although it has not been investigated with this particular ai vaccine strain, studies performed with other strains show that protective levels of serum antibody titres would be expected to persist in chickens for at least 12 months after administration of two doses of vaccine. the duration of immunity in ducks is unknown.

Európai Unió - angol - EMA (European Medicines Agency)

sanofi pasteur europe - influenza virus (inactivated, split) of the following strains:a/california/7/2009 (h1n1)pdm09 - like strain (a/california/7/2009, nymc x-179a)a/hong kong/4801/2014 (h3n2) - like strain (a/hong kong/4801/2014, nymc x-263b)b/brisbane/60/2008 - like strain (b/brisbane/60/2008, wild type) - influenza, human; immunization - vaccines - prophylaxis of influenza in individuals 60 years of age and over, especially in those who run an increased risk of associated complications.the use of intanza should be based on official recommendations.

Európai Unió - angol - EMA (European Medicines Agency)

ology bioservices ireland ltd - influenza virus (whole virion, inactivated), containing antigen of: a/vietnam/1203/2004 (h5n1) - influenza, human; immunization; disease outbreaks - influenza vaccines - active immunisation against h5n1 subtype of influenza a virus. this indication is based on immunogenicity data from subjects from the age of 6 months onwards following administration of two doses of vaccine prepared with h5n1 subtype strains. vepacel should be used in accordance with official guidance.,